INT1982

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 1977
Last Reported 2010
Negated 12
Speculated 11
Reported most in Body
Documents 119
Total Number 130
Disease Relevance 116.20
Pain Relevance 14.35

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
eyes 10
hypothalamus 5
CNS 3
superior 3
outflow 2
NARFL (Homo sapiens)
Pain Link Frequency Relevance Heat
Serotonin 316 100.00 Very High Very High Very High
Pain 299 100.00 Very High Very High Very High
anesthesia 227 100.00 Very High Very High Very High
Paracetamol 54 100.00 Very High Very High Very High
iatrogenic 6 100.00 Very High Very High Very High
sSRI 200 99.92 Very High Very High Very High
Central nervous system 47 99.86 Very High Very High Very High
lidocaine 22 99.82 Very High Very High Very High
Inflammation 258 99.72 Very High Very High Very High
ketamine 13 99.48 Very High Very High Very High
Disease Link Frequency Relevance Heat
Ocular Hypertension 8233 100.00 Very High Very High Very High
Pain 294 100.00 Very High Very High Very High
Retina Disease 88 99.92 Very High Very High Very High
Glaucoma 2446 99.86 Very High Very High Very High
INFLAMMATION 274 99.72 Very High Very High Very High
Strabismus 8 99.68 Very High Very High Very High
Hypotension 282 99.52 Very High Very High Very High
Cataract 298 99.32 Very High Very High Very High
Blister 105 99.28 Very High Very High Very High
Hypertension 102 99.22 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In some patients, IOP is not adequately controlled by monotherapy.
Neg (not) Regulation (controlled) of IOP
1) Confidence 0.49 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Abstract Doc Link PMC2698680 Disease Relevance 0.69 Pain Relevance 0.10
In some patients, IOP is not adequately controlled by monotherapy.
Neg (not) Regulation (controlled) of IOP associated with ocular hypertension
2) Confidence 0.49 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698680 Disease Relevance 1.42 Pain Relevance 0.06
Despite continued advances in laser and incisional surgery, medical therapy continues to be the primary means by which IOP is controlled (Schwartz and Bundez 2004).
Regulation (controlled) of IOP associated with ocular hypertension
3) Confidence 0.49 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698680 Disease Relevance 1.43 Pain Relevance 0.10
All subjects were seropositive for anti-FHA and anti-PRN but 4% of the initially seronegatives in both reduced aluminium groups did not seroconvert for anti-PT.
Regulation (seropositive) of PRN
4) Confidence 0.44 Published 2005 Journal Vaccine Section Abstract Doc Link 15670888 Disease Relevance 0.32 Pain Relevance 0.12
Two or more medications were added if necessary to control the IOP.
Regulation (control) of IOP associated with ocular hypertension
5) Confidence 0.38 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2693970 Disease Relevance 0.58 Pain Relevance 0.07
Specific comparison will be the effect of time contingent paracetamol on secondary outcome measures (pain intensity, disability, function, GPE and sleep quality) compared to PRN paracetamol or placebo.
Regulation (effect) of PRN associated with pain and paracetamol
6) Confidence 0.34 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2918542 Disease Relevance 0.27 Pain Relevance 0.47
After the IOP was controlled, the pupil became fixed and dilated.
Regulation (controlled) of IOP in pupil associated with ocular hypertension
7) Confidence 0.24 Published 2006 Journal J Cataract Refract Surg Section Abstract Doc Link 16516801 Disease Relevance 0.56 Pain Relevance 0.09
The European Latanoprost Study Group randomized 226 patients whose IOP was insufficiently controlled by timolol alone to receive either latanoprost once daily or the FCDT twice daily.
Regulation (controlled) of IOP associated with ocular hypertension
8) Confidence 0.23 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2693974 Disease Relevance 0.81 Pain Relevance 0
The results of their studies indicate that the fixed combination was as at least as effective as its components given concomitantly in controlling IOP (no statistically significant difference).
Regulation (controlling) of IOP associated with ocular hypertension
9) Confidence 0.23 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2693974 Disease Relevance 0.69 Pain Relevance 0
Patients had better diurnal IOP control with bimatoprost than FCDT.
Regulation (control) of IOP associated with ocular hypertension
10) Confidence 0.23 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2693974 Disease Relevance 0.96 Pain Relevance 0.05
In 253 patients whose IOP was inadequately controlled on timolol montherapy, the Dorzolamide-Timolol Combination Study Group also found that the FCDT was superior to either of the components given individually in lowering the IOP and is as well-tolerated as the dorzolamide component.
Regulation (controlled) of IOP in superior associated with ocular hypertension
11) Confidence 0.23 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2693974 Disease Relevance 0.72 Pain Relevance 0
The relevance of this hypothesis with regard to a possible central regulation of IOP is discussed.
Spec (possible) Regulation (regulation) of IOP associated with ocular hypertension
12) Confidence 0.22 Published 1979 Journal Albrecht Von Graefes Arch Klin Exp Ophthalmol Section Abstract Doc Link 312040 Disease Relevance 0.55 Pain Relevance 0.47
The present study indicates the controlling effect of serotonin and ketanserin on the IOP.
Regulation (effect) of IOP associated with ocular hypertension and serotonin
13) Confidence 0.22 Published 1987 Journal J Ocul Pharmacol Section Abstract Doc Link 3503917 Disease Relevance 1.35 Pain Relevance 0.33
While atracurium with or without lidocaine did not affect IOP following complete suppression of train-of-four (groups A, B, and C), succinylcholine per se or in combination with lidocaine (groups F and G) significantly (p less than 0.01) increased IOP after induction with thiopentone but not exceeding the baseline IOP level.
Neg (not) Regulation (affect) of IOP associated with ocular hypertension and lidocaine
14) Confidence 0.22 Published 1992 Journal Acta Anaesthesiol Belg Section Abstract Doc Link 1632179 Disease Relevance 0.82 Pain Relevance 0.55
The use of lidocaine in combination with atracurium (group D) or succinylcholine (group G) for a rapid sequence intubation did not affect IOP following endotracheal intubation.
Neg (not) Regulation (affect) of IOP associated with ocular hypertension and lidocaine
15) Confidence 0.22 Published 1992 Journal Acta Anaesthesiol Belg Section Abstract Doc Link 1632179 Disease Relevance 0.63 Pain Relevance 0.29
No significant change of IOP in the contralateral eye was observed with these drugs.
Neg (No) Regulation (change) of IOP in eye associated with ocular hypertension
16) Confidence 0.22 Published 1992 Journal Nippon Ganka Gakkai Zasshi Section Abstract Doc Link 1348394 Disease Relevance 1.06 Pain Relevance 0.47
Ketanserin, a specific 5-HT2A antagonist, counteracts the IOP increase brought about by fluoxetine, thus emphasizing the role of serotonin in the regulation of IOP and stressing the importance of including ophthalmological examination in the protocol of depressed patients undergoing SSRI therapy.
Regulation (regulation) of IOP associated with antagonist, ocular hypertension, ssri, serotonin and fluoxetine
17) Confidence 0.22 Published 2000 Journal Exp. Eye Res. Section Abstract Doc Link 10870512 Disease Relevance 0.81 Pain Relevance 0.72
METHODS: Thirty patients with uncontrolled IOP and advanced glaucoma were divided on clinical grounds into two groups and were treated with either a half or a full standardized dose of laser (40 x 1500 mW for 1500 ms) and monitored for IOP control, visual acuity, postoperative inflammation and phthisis.
Regulation (control) of IOP
18) Confidence 0.22 Published 1998 Journal Aust N Z J Ophthalmol Section Body Doc Link 9630294 Disease Relevance 0 Pain Relevance 0
Peak values of IOP during both ketamine sedation and ketamine-pentobarbital anesthesia were reached 3 to 5 minutes after administration of the drug(s).
Regulation (values) of IOP associated with anesthesia, ketamine, sleep disorders and ocular hypertension
19) Confidence 0.22 Published 1977 Journal Invest. Ophthalmol. Vis. Sci. Section Abstract Doc Link 863613 Disease Relevance 0.89 Pain Relevance 0.86
CONCLUSION: Diode laser cyclophotocoagulation appears to be simple, safe and is frequently successful in the control of IOP in end-stage glaucoma.
Regulation (control) of IOP
20) Confidence 0.22 Published 1998 Journal Aust N Z J Ophthalmol Section Body Doc Link 9630294 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox